SCHEMBL26972607

SCHEMBL26972607

CC[C@H]1CN(c2ccccn2)C[C@@H](C)O1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.43
ALDH1A1 P00352 4/20 0.43
MAPT P10636 1/20 0.43
GRIN2B Q13224 2/20 0.43
GAA P10253 1/20 0.43
CHI3L1 P36222 1/20 0.42
KCNH2 Q12809 1/20 0.42
CHIT1 Q13231 1/20 0.42
CHI3L2 Q15782 1/20 0.42
CHIA Q9BZP6 1/20 0.42
HSD11B1 P28845 1/20 0.41
HSD17B10 Q99714 1/20 0.40
DRD4 P21917 2/20 0.40
GRM1 Q13255 1/20 0.40
PLD1 Q13393 1/20 0.40
KMT2A Q03164 1/20 0.39
HTR7 P34969 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29505307 0.86 ALDH1A1 (0.50) KDM4EALDH1A1MAPTGRIN2BGAA
SCHEMBL30378346 0.86 ALDH1A1 (0.50) KDM4EALDH1A1MAPTGRIN2BGAA
SCHEMBL23875355 0.86 ALDH1A1 (0.50) KDM4EALDH1A1MAPTGRIN2BGAA
SCHEMBL26972635 0.82 LRRK2 (0.39) KDM4EALDH1A1MAPTGAAGRM1
SCHEMBL5341226 0.79 DPP4 (0.43) KDM4EALDH1A1MAPTGRIN2BGAA
Formamide SCHEMBL28688411 0.78 HSD11B1 (0.44) KDM4EALDH1A1MAPTGRIN2BGAA
SCHEMBL23875674 0.77 KDM4E (0.47) KDM4EALDH1A1MAPTGRIN2BHSD17B10
SCHEMBL20204378 0.76 GRM2 (0.42) KDM4EALDH1A1MAPTGAAKCNH2
SCHEMBL26974647 0.76 LRRK2 (0.36) KDM4EALDH1A1GAACHI3L1KCNH2
SCHEMBL23875357 0.75 CHI3L1 (0.46) KDM4EALDH1A1MAPTGRIN2BCHI3L1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858940-B2 Selective modulators of mutant LRRK2 proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2024-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11858940-B2 Selective modulators of mutant LRRK2 proteolysis and associated methods of use LRRK2, ADRM1, CRBN KDM4E 1434/4885ALDH1A1 4021/4885MAPT 673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.